Skip to main content

Table 3 Other outcomes, change in outcome at study end from baseline

From: Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial

  Testosterone group
n = 49
Placebo group
n = 51
Between group P valuea
BMI, kg/m2 –3.7* (–4.7 to –2.7) –3.6* (–4.8 to –2.3) –0.1 (–1.7 to 1.4) 0.85
Waist circumference, cm –11* (–14 to –8) –8* (–12 to –5) –3 (–7 to 2) 0.21
SBP, mmHg –1 (–6 to 3) –1 (–6 to 3) 0 (–6 to 6) 0.94
DBP, mmHg 0 (–3 to 3) –1 (–4 to 2) 1 (–3 to 5) 0.62
Handgrip, kg 1.7 (–0.5 to 3.8) –1.9 (–4.3 to 0.5) 3.6 (0.4 to 6.7) 0.03
ALM/height2, kg/m2 0.12 (–0.02 to 0.26) –0.33* (–0.50 to –0.15) 0.45 (0.22 to 0.67) <0.001
Step count per day 931* (116 to 1746) 606 (–186 to 1399) 325 (–794 to 1443) 0.56
Activity, %/day 1.5* (0.1 to 2.9) 0.7 (–0.6 to 2.1) 0.76 (–1.2 to 2.7) 0.43
Physical function test, sec –3.1* (–4.8 to –1.5) –2.7* (–4.1 to –1.3) –0.4 (–2.6 to 1.7) 0.67
TT, nmol/L, ECLIA 7.4* (5.7 to 9.1) 1.8* (0.4 to 3.1) 5.5 (3.4 to 7.7) <0.001
cFT, pmol/L, ECLIA 49* (37 to 60) 4 (–3 to 10) 46 (32 to 59) <0.001
SHBG, nmol/L 4* (2 to 6) 7* (3 to 10) –3 (–6.4 to 1.1) 0.16
LH, IU/L –4.0* (–4.7 to –3.4) 0.2 (–0.5 to 1.0) –4.3 (–5.2 to –3.3) <0.001
Fasting glucose, mmol/L –0.5* (–0.8 to –0.25) –0.3* (–0.5 to 0.0) –0.3 (–0.6 to 0.1) 0.19
HOMA-IR –0.8* (–1.1 to –0.5) –0.6* (–0.9 to –0.2) –0.2 (–0.7 to 0.3) 0.38
HbA1c, % –0.5* (–0.6 to –0.3) –0.3* (–0.5 to –0.2) –0.1 (–0.3 to 0.1) 0.19
Cholesterol, mmol/L –0.18 (–0.4 to 0.0) 0.0 (–0.2 to 0.2) –0.19 (–0.5 to 0.1) 0.23
LDL-C, mmol/L –0.1 (–0.3 to 0.1) –0.1 (–0.3 to 0.2) 0.0 (–0.3 to 0.3) 0.88
HDL-C, mmol/L 0.1* (0.1 to 0.2) 0.1* (0.0 to 0.2) 0.0 (–0.1 to 0.1) 0.66
Triglycerides, mmol/L –0.6* (–0.9 to –0.4) –0.4* (–0.6 to –0.1) –0.3 (–0.6 to 0.1) 0.17
Haematocrit 0.04* (0.03 to 0.05) –0.005* (–0.009 to –0.001) 0.04 (0.03 to 0.05) <0.001
Haemoglobin, g/L 14* (11 to 17) –2* (–3 to 0) 15 (12 to 19) <0.001
PSA, μg/L 0.3* (0.2 to 0.5) 0.1* (0.0 to 0.3) 0.2 (0.0 to 0.4) 0.10
  1. Shown are within- and between-group differences between baseline and study end
  2. The data are mean (95 % CI).
  3. aP value refers to difference between groups at study end
  4. *P < 0.05 versus baseline within group
  5. BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, ALM appendicular lean mass, VAT visceral abdominal tissue, SHBG sex hormone binding globulin, TT testosterone, cFT calculated free testosterone, ECLIA electrochemiluminescence immunoassay, LCMS liquid chromatography-tandem mass spectroscopy, LH luteinising hormone, HbA1c glycated haemoglobin, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, PSA Prostate-specific antigen